Researchers develop a photopharmaceutical analogue of vitamin D to treat psoriasis with light, reducing side effects
A new class of photosensitive molecule is being developed that allows the vitamin D receptor to be modulated without side effects.
An international study confirms two equally effective treatment options for patients with advanced pancreatic neuroendocrine tumours
It is the first large-scale and well-controlled study that shows that chemotherapy works in this type of tumor, and is well tolerated when compared to a common treatment such as everolimus.
Notch signaling opens the way to a novel blood rejuvenating approach
IDIBELL researchers identify the role of Notch signaling alterations in inducing blood aging, which manifests as myeloid skewing, reduced regenerative capacity and clonal expansion of old stem cells.
Notch signaling opens the way to a novel blood rejuvenating approach Read More »
An international study, with outstanding participation of Bellvitge, identifies the first treatment for Rendu-Osler disease
Engarsertib is an oral molecule designed exclusively for the disease, able to significantly reduce severe nasal bleeding that can last for hours and forces repeated transfusions.
A mechanism that facilitates the elimination of cells that we no longer need has been discovered
Researchers at IDIBELL-CSIC discover and film how cells that eliminate other dead cells “chew” them to fragment them.
IDIBELL professionals participate in the 17th Collaborative Conference of the Bachelor’s Degree in Biomedicine of the UB
A meeting to strengthen the link between academic training and clinical research to promote the future of biomedicine.
Double advance in ovarian cancer: targeting a pseudogene shrinks the tumor in preclinical models and paves the way for new targeted therapies
The blockade of an specific pseudogene in ovarian cancer reduces tumor growth without showing obvious signs of toxicity.
The universal CAR-T proposal of the THOR project wins the IV edition of the VTSO-XarSMART Health Innovation Awards
The winner was the THOR project, from IDIBELL, a universal and modular CAR-T therapy that allows the treatment of various tumors.
Bellvitge researchers detect for the first time in Spain a rare mechanism of bacterial resistance
This is the first time in Spain and the second time in Europe that this bacterial resistance mechanism has been detected.
Bellvitge, a la recerca del futur: an exhibition at the Metro station recalls the creation of the neighbourhood, the arrival of the Metro and the development of the Health Campus
The exhibition Bellvitge, a la recerca del futur, opens promoted by IDIBELL